# EDGAR Filing Document

**Accession Number:** 0001779020
**File Stem:** 0001209191-23-021895
**Filing Date:** 2023-3
**Character Count:** 11074
**Document Hash:** 081f01e0c4adf3a230f1f3114e9bc760
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-021895.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0001209191-23-021895

**CONFORMED SUBMISSION TYPE**: 4/A

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230228

**FILED AS OF DATE**: 20230331

**DATE AS OF CHANGE**: 20230331

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** CROSKREY STEPHEN
- **CENTRAL INDEX KEY:** 0001140350

**FILING VALUES:**
- **FORM TYPE:** 4/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39280
- **FILM NUMBER:** 23788906

**MAIL ADDRESS:**
- **STREET 1:** C/O ARMOR HOLDINGS INC
- **STREET 2:** 1400 MARSH LANDING PARKWAY SUITE 112
- **CITY:** JACKSONVILLE
- **STATE:** FL
- **ZIP:** 32250
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Danimer Scientific, Inc.
- **CENTRAL INDEX KEY:** 0001779020
- **STANDARD INDUSTRIAL CLASSIFICATION:** PLASTICS, MATERIALS, SYNTH RESINS & NONVULCAN ELASTOMERS [2821]
- **IRS NUMBER:** 841924518
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 140 INDUSTRIAL BOULEVARD
- **CITY:** BAINBRIDGE
- **STATE:** GA
- **ZIP:** 39817
- **BUSINESS PHONE:** 229-243-7075

**MAIL ADDRESS:**
- **STREET 1:** 140 INDUSTRIAL BOULEVARD
- **CITY:** BAINBRIDGE
- **STATE:** GA
- **ZIP:** 39817

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Danimer Scientific, Inc
- **DATE OF NAME CHANGE:** 20201229

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Live Oak Acquisition Corp
- **DATE OF NAME CHANGE:** 20200106

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Foxhound Merger Partners, Inc.
- **DATE OF NAME CHANGE:** 20190605

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4/A

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>CROSKREY STEPHEN<br><sub>(Last) (First) (Middle)</sub><br>C/O DANIMER SCIENTIFIC, INC.<br>140 INDUSTRIAL BOULEVARD<br><sub>(Street)</sub><br>BAINBRIDGE, GA 39817<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-28 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CEO & Chairman of the Board_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Danimer Scientific, Inc. [ DNMR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option | $2.58 | 2023-02-28 |  | A |  | 750000<sup>(1)</sup> |  | <sup>(2)</sup> | 2033-02-28 | Common Stock | 750000 | $0.00 | 750000 | D |  |
| Stock Option | $7.50 | 2023-02-28 |  | A |  | 300000<sup>(1)</sup> |  | <sup>(3)</sup> | 2033-02-28 | Common Stock | 300000 | $0.00 | 300000 | D |  |
| Performance Stock Award | $0.00 | 2023-02-28 |  | A |  | 385000<sup>(4)</sup> |  | <sup>(5)(6)(7)(8)(9)</sup> | <sup>(10)</sup> | Common Stock | 385000 | $0.00 | 385000 | D |  |

---

### Footnotes:

(1) On March 2, 2023, the reporting person filed a Form 4 that inadvertently reported a stock option award of 1,305,970 options based on incorrect data. This Form 4/A is being filed to correct the error by reflecting the correct number of options that were awarded in the form of two separate grants with two separate exercise prices applicable to the awards.

(2) The option to purchase shares of the Issuer's Class A common stock ("Common Stock") was granted to Reporting Person on February 28, 2023 under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (the "Plan"). Options to purchase 250,000 shares of the Issuer's Common Stock will vest and become exercisable on each of February 28, 2024, February 28, 2025, and February 28, 2026; provided that, to the extent necessary, the option will not be exercisable until the approval of the shareholders of the Issuer of an amendment to the Plan to increase the number of shares available under the Plan in an amount sufficient to permit the exercise of the option.

(3) The option to purchase shares of the Issuer's Common Stock was granted to Reporting Person on February 28, 2023, under the Plan. Options to purchase 100,000 shares of the Issuer's Common Stock will vest and become exercisable on each of February 28, 2024, February 28, 2025, and February 28, 2026; provided that, to the extent necessary, the option will not be exercisable until the approval of the shareholders of the Issuer of an amendment to the Plan to increase the number of shares available under the Plan in an amount sufficient to permit the exercise of the option.

(4) On March 2, 2023, the reporting person filed a Form 4 that inadvertently reported a Performance Stock Award of 678,295 performance shares based on incorrect data. This Form 4/A is being filed to correct the error by reflecting the correct number of performance shares.

(5) Comprised of a performance stock award (the "PSA") granted under the Plan consisting of 385,000 performance shares of the Common Stock (the "Performance Shares").

(6) Under the PSA, the Performance Shares will be issued only if (A) to the extent necessary, after the approval of the shareholders of the Issuer of an amendment to the Plan to increase the number of shares available under the Plan in an amount sufficient to permit the vesting and issuance of the Performance Shares in accordance with the PSA, and (B) they have vested in accordance with the following vesting criteria:

(7) (i) 50% of the Performance Shares (the "Total PHA Revenue Metric Shares") will be subject to vesting upon achievement of the Total PHA Revenue metric as follows: the threshold for vesting the Total PHA Revenue Metric Shares will be the Issuer achieving Total PHA Revenue of at least $177 million, in which event 50% of the Total PHA Revenue Metric Shares will vest, and upon the Issuer achieving Total PHA Revenue of $202 million, 100% of the Total PHA Revenue Metric Shares will vest, with pro rata vesting of the Total PHA Revenue Metric Shares for any amount of Total PHA Revenue in between such ranges;

(8) (ii) 50% of the Performance Shares (the "Adjusted EBITDA Metric Shares") will be subject to vesting upon achievement of the earnings before interest, taxes, depreciation and amortization, including all adjustments made for reporting this metric in public filings ("Adjusted EBITDA") metric as follows: the threshold for vesting the Adjusted EBITDA Metric Shares will be the Issuer achieving Adjusted EBITDA of at least $36 million, in which event 50% of the Adjusted EBITDA Metric Shares will vest, and upon the Issuer achieving $44 million of Adjusted EBITDA, 100% of the Adjusted EBITDA Metric Shares will vest, with pro rata vesting of the Adjusted EBITDA Metric Shares for any amount of Adjusted EBITDA in between such ranges.

(9) Total PHA Revenue will mean the Total PHA Revenue for the Issuer based upon the Company's audited consolidated financial statements for the fiscal year ended December 31, 2025.  Adjusted EBITDA will be determined based on the Issuer's consolidated financial statements for the period in question.  The vesting of the Adjusted EBITDA Metric Shares will be determined based on the Issuer's audited consolidated financial statements for the fiscal year ended December 31, 2025.

(10) The earlier of (i) March 31, 2026 or such reasonable time thereafter to allow the Compensation Committee of the Board of Directors of the Issuer to receive the Company's audited consolidated financial statements for the fiscal year ended December 31, 2025, to ratify achieved performance against relevant metrics, and to issue the number of Performance Shares vested in accordance therewith or (ii) the Reporting Person's Termination Date (as defined in the Plan).

**Signature:** /s/ Stephen A. Martin, attorney-in-fact  
**Date:** 2023-03-31

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**